ZURICH (Reuters) – The funding car of the Sandoz household will get 2.6 billion Swiss francs ($2.90 billion) from promoting a piece of Swiss pharma big Novartis, the bookrunner on the deal stated on Wednesday.
Emasan AG bought 26.5 million shares at a worth of 98.25 Swiss francs in an accelerated bookbuilt providing, Goldman Sachs stated.
The household basis didn’t reply to a request for remark.
In keeping with LSEG knowledge, the Sandoz household was the third largest shareholder in Novartis with a stake of 4.1%. This positioned them behind BlackRock with 6.4% and UBS with 5.3%.
Novartis stated the stake being bought by Emasan corresponded to roughly 1% of its excellent shares.
“The overwhelming majority of our shareholders are institutional traders with a long-term view, and we count on this to proceed,” a Novartis spokesperson stated.
Sandoz was one of many two predecessor firms of Novartis. The pharmaceutical big emerged in 1996 from the merger of the corporate with the pharmaceutical and chemical group Ciba-Geigy.
($1 = 0.8951 Swiss francs)
(Reporting by Alexander Hubner and Oliver Hirt, writing by John Revill; Modifying by Sharon Singleton)